Final skin toxicity and patient‑reported outcomes results from PRIME: A randomized phase 3 study of panitumumab + FOLFOX4 for 1st‑line metastatic colorectal cancer Jean‑Yves…
Final skin toxicity and patient‑reported outcomes results from PRIME: A randomized phase 3 study of panitumumab + FOLFOX4 for 1st‑line metastatic colorectal cancer Jean‑Yves…